1. Home
  2. MDXH vs SRG Comparison

MDXH vs SRG Comparison

Compare MDXH & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • SRG
  • Stock Information
  • Founded
  • MDXH 2003
  • SRG 2014
  • Country
  • MDXH Belgium
  • SRG United States
  • Employees
  • MDXH N/A
  • SRG N/A
  • Industry
  • MDXH
  • SRG Real Estate Investment Trusts
  • Sector
  • MDXH
  • SRG Real Estate
  • Exchange
  • MDXH Nasdaq
  • SRG Nasdaq
  • Market Cap
  • MDXH 203.4M
  • SRG 236.0M
  • IPO Year
  • MDXH 2021
  • SRG 2015
  • Fundamental
  • Price
  • MDXH $3.28
  • SRG $3.46
  • Analyst Decision
  • MDXH Strong Buy
  • SRG
  • Analyst Count
  • MDXH 3
  • SRG 0
  • Target Price
  • MDXH $7.67
  • SRG N/A
  • AVG Volume (30 Days)
  • MDXH 333.0K
  • SRG 151.7K
  • Earning Date
  • MDXH 11-12-2025
  • SRG 11-14-2025
  • Dividend Yield
  • MDXH N/A
  • SRG N/A
  • EPS Growth
  • MDXH N/A
  • SRG N/A
  • EPS
  • MDXH N/A
  • SRG N/A
  • Revenue
  • MDXH $103,069,000.00
  • SRG $15,365,000.00
  • Revenue This Year
  • MDXH $24.78
  • SRG N/A
  • Revenue Next Year
  • MDXH $21.20
  • SRG N/A
  • P/E Ratio
  • MDXH N/A
  • SRG N/A
  • Revenue Growth
  • MDXH 21.68
  • SRG N/A
  • 52 Week Low
  • MDXH $1.35
  • SRG $2.43
  • 52 Week High
  • MDXH $5.33
  • SRG $4.72
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 26.74
  • SRG 27.42
  • Support Level
  • MDXH $2.75
  • SRG $3.97
  • Resistance Level
  • MDXH $4.98
  • SRG $4.23
  • Average True Range (ATR)
  • MDXH 0.28
  • SRG 0.14
  • MACD
  • MDXH -0.17
  • SRG -0.08
  • Stochastic Oscillator
  • MDXH 23.45
  • SRG 0.64

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About SRG Seritage Growth Properties

Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.

Share on Social Networks: